Loading...
ATRA logo

Atara Biotherapeutics, Inc.NasdaqGS:ATRA Stock Report

Market Cap US$80.1m
Share Price
US$9.45
US$13.67
30.9% undervalued intrinsic discount
1Y37.0%
7D-9.8%
Portfolio Value
​
View

Atara Biotherapeutics, Inc.

NasdaqGS:ATRA Stock Report

Market Cap: US$80.1m

Atara Biotherapeutics (ATRA) Stock Overview

Engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. More details

ATRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Earnings are forecast to grow 51.11% per year

Earnings have grown 38.7% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($80M)

+ 1 more risk

ATRA Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Atara Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Atara Biotherapeutics
Historical stock prices
Current Share PriceUS$9.45
52 Week HighUS$19.15
52 Week LowUS$3.92
Beta-0.29
1 Month Change89.38%
3 Month Change122.88%
1 Year Change36.96%
3 Year Change-80.31%
5 Year Change-97.22%
Change since IPO-96.85%

Recent News & Updates

Recent updates

Analysis Article • Feb 16

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Atara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong...
Seeking Alpha • Nov 30

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Summary Atara Biotherapeutics is on the precipice of being behind an FDA approval for a novel cell therapy. However, they do not hold the rights for this cell therapy's commercialization. Furthermore, ATRA has suspended development of their pipeline, meaning there are few, if any, catalysts to justify buying in. Read the full article on Seeking Alpha
Analysis Article • Oct 09

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 30% gain in the last...
Analysis Article • Aug 13

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...
Analysis Article • May 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article • May 01

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 07

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Unfortunately for some shareholders, the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price has dived 27% in the...
Seeking Alpha • Jan 21

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Summary Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on cash runway, considering delay in milestone payments related to approval as well as future royalties. Nevertheless, ATRA remains eligible for these future payments. This forced ATRA to suspend its CAR-T pipeline in search for strategic alternatives. On the bright side, this creates another short-term catalyst and allows ATRA to focus resources on EBVALLO. ATRA estimates that available cash along a newly announced $15M equity line of credit are sufficient to fund operations through approval, but the risk of further cash raise is real. Read the full article on Seeking Alpha
Analysis Article • Jan 16

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...
Analysis Article • Jan 07

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders have had their patience rewarded with a 34% share price jump...
Analysis Article • Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Those holding Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares would be relieved that the share price has rebounded...
Analysis Article • Jul 21

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...
Seeking Alpha • Jul 03

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Summary Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. Assuming no regulatory delays ATRA is well-funded to deliver proof-of-concept clinical data for its CAR-T platform in both B-cell malignancies and lupus, with an estimated cash runway into 2027. Despite fierce competition, ATRA's differentiated CAR-T platform combines all the best attributes of the competition, thus having a best-in-class potential. The major short-term risk is regulatory delays, meaning delays in pending regulatory milestone payments, which would likely necessitate a cash raise. Read the full article on Seeking Alpha
Analysis Article • May 14

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Shareholders in Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) may be thrilled to learn that the analysts have just...
Analysis Article • May 11

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

To the annoyance of some shareholders, Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares are down a considerable 26...
Seeking Alpha • Feb 06

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Summary Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway. Read the full article on Seeking Alpha

Shareholder Returns

ATRAUS BiotechsUS Market
7D-9.8%-3.0%-0.3%
1Y37.0%32.9%26.7%

Return vs Industry: ATRA exceeded the US Biotechs industry which returned 28.1% over the past year.

Return vs Market: ATRA exceeded the US Market which returned 23.3% over the past year.

Price Volatility

Is ATRA's price volatile compared to industry and market?
ATRA volatility
ATRA Average Weekly Movement30.8%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: ATRA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ATRA's weekly volatility has increased from 20% to 31% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201214Cokey Nguyenwww.atarabio.com

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.

Atara Biotherapeutics, Inc. Fundamentals Summary

How do Atara Biotherapeutics's earnings and revenue compare to its market cap?
ATRA fundamental statistics
Market capUS$80.10m
Earnings (TTM)-US$9.47m
Revenue (TTM)US$23.14m
3.5x
P/S Ratio
-8.5x
P/E Ratio

Is ATRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATRA income statement (TTM)
RevenueUS$23.14m
Cost of RevenueUS$25.84m
Gross Profit-US$2.70m
Other ExpensesUS$6.77m
Earnings-US$9.47m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.11
Gross Margin-11.66%
Net Profit Margin-40.91%
Debt/Equity Ratio0%

How did ATRA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 12:50
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Yigal NochomovitzCitigroup Inc
Michael KingCitizens JMP Securities, LLC